Christopher C Fraser

This inventor holds 26 USPTO granted patents and 26 published patent applications and 6 EPO patents, primarily in Synthetic Nanocarriers. Top assignees: Millennium Pharmaceuticals Limited, Selecta Biosciences, Inc.. Active years: 2003-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher C Fraser. Retrieved from https://idiyas.com/inventor/christopher-c-fraser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 26)

% Patents Active = 61.5

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 1.8

ph-index = 11

Forward Citations = 378(Granted Patents)

Location History:

Lexington, MA (US) (2003 - 2012)
Arlington, MA (US) (2013 - 2023)

Company Filing History:

15 out of 854

Millennium Pharmaceuticals Limited

patents

11 out of 32

Selecta Biosciences, Inc.

patents

Years Active: 2003-2023

Loading Chart...

Areas of Expertise:

Tolerogenic Nanocarriers

CD8+ Regulatory T Cells

Antigen-Specific Deletion

Therapeutic Proteins

Cytotoxic T Lymphocyte

Immunostimulatory Oligonucleotides

TANGO240

B7-H2 Polypeptides

Nucleic Acids

Polypeptides

Screening Methods

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11779641 - Tolerogenic synthetic nanocarriers for allergy therapy (2023-10-10),

2. 11717569 - Tolerogenic synthetic nanocarriers (2023-08-08),

3. 10441651 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2019-10-15),

4. 10420835 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2019-09-24),

5. 10004802 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2018-06-26),

6. 9987354 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2018-06-05),

7. 9295718 - Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins (2016-03-29),

8. 9289477 - Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses (2016-03-22),

9. 9289476 - Tolerogenic synthetic nanocarriers for allergy therapy (2016-03-22),

10. 9265815 - Tolerogenic synthetic nanocarriers (2016-02-23),

11. 8754199 - Tango 240 nucleic acids and uses thereof (2014-06-17),

12. 8546550 - Immunostimulatory oligonucleotides (2013-10-01),

13. 8187819 - Methods of identifying compounds that bind TANGO240 (2012-05-29),

14. 8076086 - Methods of modulating the activity of TANGO332 (2011-12-13),

15. 7544491 - TANGO 240 nucleic acids and uses thereof (2009-06-09),

Title: Christopher C. Fraser: Innovator in Allergy Therapy

Introduction

Christopher C. Fraser, based in Lexington, MA, is an accomplished inventor known for his significant contributions to the field of allergy therapy. With a remarkable portfolio of 26 patents, Fraser's work focuses on developing innovative synthetic nanocarrier technologies aimed at improving immune responses related to allergies.

Latest Patents

Fraser's latest patents showcase his dedication to advancing allergy treatments. One of his noteworthy inventions, titled "Tolerogenic Synthetic Nanocarriers for Allergy Therapy," discloses synthetic nanocarrier compositions that include immunosuppressants and MHC Class II-restricted epitopes of allergens. These compositions are designed to induce tolerogenic immune responses specific to allergens, offering a potential breakthrough in allergy management. Additionally, he developed another patent, "Tolerogenic Synthetic Nanocarriers," which describes compositions that incorporate synthetic nanocarriers and immunosuppressants, leading to immune suppressive effects. Some of these compositions can also include antigen, enabling antigen-specific tolerogenic immune responses.

Career Highlights

Throughout his career, Christopher C. Fraser has had the opportunity to work with notable companies in the biotechnology sector. He has significantly contributed to Millennium Pharmaceuticals Limited and Selecta Biosciences, Inc., where he applied his innovative ideas to develop therapeutic solutions.

Collaborations

Fraser's journey has been marked by fruitful collaborations with esteemed colleagues, including Roberto A. Maldonado and Takashi Kei Kishimoto. Their joint efforts have furthered the exploration of synthetic nanocarrier technologies, driving advancements in allergy therapies.

Conclusion

In conclusion, Christopher C. Fraser's innovative work and dedication to developing synthetic nanocarrier technologies represent a significant stride forward in allergy therapy. His extensive patent portfolio and professional collaborations underscore his influence in the field, making him a respected figure in the innovation and invention landscape.

Profile summary based on public USPTO records.